Signaturefd LLC Purchases 577 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Signaturefd LLC increased its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 53.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,652 shares of the medical research company’s stock after purchasing an additional 577 shares during the quarter. Signaturefd LLC’s holdings in Exact Sciences were worth $113,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Daiwa Securities Group Inc. lifted its position in Exact Sciences by 1.7% during the first quarter. Daiwa Securities Group Inc. now owns 11,947 shares of the medical research company’s stock worth $825,000 after purchasing an additional 200 shares during the period. Amalgamated Bank lifted its position in Exact Sciences by 2.7% during the second quarter. Amalgamated Bank now owns 10,937 shares of the medical research company’s stock worth $462,000 after purchasing an additional 284 shares during the period. Midwest Professional Planners LTD. lifted its holdings in shares of Exact Sciences by 12.3% in the first quarter. Midwest Professional Planners LTD. now owns 3,088 shares of the medical research company’s stock worth $213,000 after acquiring an additional 339 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Exact Sciences by 92.4% in the first quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock worth $49,000 after acquiring an additional 340 shares during the last quarter. Finally, CIBC Asset Management Inc lifted its holdings in shares of Exact Sciences by 6.2% in the second quarter. CIBC Asset Management Inc now owns 6,118 shares of the medical research company’s stock worth $258,000 after acquiring an additional 356 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.

Insiders Place Their Bets

In other Exact Sciences news, EVP Brian Baranick sold 929 shares of the stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the transaction, the executive vice president now directly owns 12,758 shares in the company, valued at approximately $893,060. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.36% of the company’s stock.

Exact Sciences Price Performance

Exact Sciences stock opened at $69.35 on Tuesday. The stock has a market capitalization of $12.80 billion, a price-to-earnings ratio of -52.54 and a beta of 1.27. Exact Sciences Co. has a 52-week low of $40.62 and a 52-week high of $79.62. The stock’s 50 day moving average price is $65.98 and its two-hundred day moving average price is $56.43. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.98 and a current ratio of 2.17.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.28. The firm had revenue of $699.26 million for the quarter, compared to analysts’ expectations of $690.02 million. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.45) EPS. On average, equities analysts predict that Exact Sciences Co. will post -0.87 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on EXAS. Stifel Nicolaus dropped their target price on shares of Exact Sciences from $100.00 to $82.00 and set a “buy” rating for the company in a report on Thursday, August 1st. The Goldman Sachs Group dropped their target price on shares of Exact Sciences from $88.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, July 17th. Evercore ISI increased their target price on shares of Exact Sciences from $72.00 to $80.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Canaccord Genuity Group reissued a “buy” rating and issued a $75.00 target price on shares of Exact Sciences in a report on Friday, September 13th. Finally, Raymond James reaffirmed a “market perform” rating on shares of Exact Sciences in a research note on Thursday, September 26th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $78.38.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.